Prostate Cell News Volume 5.27 | Jul 25 2014

DAB2IP Regulates Cancer Stem Cell Phenotypes through Modulating Stem Cell Factor Receptor and ZEB1
DAB2IP is able to inhibit c-kit-PI3K-Akt-mTOR signaling pathway that increases c-myc protein to activate ZEB1 gene expression leading to the elevated cancer stem cell phenotypes. Elevated expression of ZEB1 and CD117 were found in the prostate basal cell population of DAB2IP knockout mice. [Oncogene] Abstract

Important Role of SUMOylation of Spliceosome Factors in Prostate Cancer Cells
Researchers identified the small ubiquitin-like modifier (SUMO)proteome of PC3 cells and revealed that SUMOylation of spliceosome factors may be implicated in the pathogenesis of prostate cancer. [J Proteome Res] Abstract | Graphical Abstract

Antiproliferative Activity of Novel Imidazopyridine Derivatives on Castration-Resistant Human Prostate Cancer Cells
Antiproliferative activities of novel imidazopyridines were compared. Among three derivatives, PHE, AMD and AMN, examined, AMD showed the highest inhibitory activity on LNCaP C-81 cell proliferation, following dose- and time-dependent manner. Additionally, AMD exhibited significant antiproliferative effect against a panel of prostate cancer cells, but not normal prostate epithelial cells. [Cancer Lett] Abstract

Redirection of CD4⁺ and CD8⁺ T Lymphocytes via a Novel Antibody-Based Modular Targeting System Triggers Efficient Killing of PSCA⁺ Prostate Tumor Cells
Researchers describe a novel modular system for treatment of prostate cancer by retargeting of T cells to the prostate stem cell antigen (PSCA). Functionality of the novel PSCA-specific modular system was investigated in vitro by T cell activation and chromium release assays as well as in immunodeficient mice. [Prostate] Abstract

Differentiation of Human Umbilical Cord Mesenchymal Stem Cells into Prostate-Like Epithelial Cells In Vivo
Researchers report that when human umbilical cord mesenchymal stem cells were combined with rat urogenital sinus stromal cells and transplanted into the renal capsule in vivo, they could differentiate into prostate epithelial-like cells that could be verified by prostate epithelial cell-specific markers including the prostate specific antigen. [PLoS One] Full Article

Inhibition of the Androgen Receptor by Mineralocorticoids at Levels Physiologically Achieved in Serum in Patients Treated with Abiraterone Acetate
Scientists elucidated the biological significance of elevated mineralocorticoid levels on androgen receptor activity in prostate cancer cells. [Prostate Cancer Prostatic Dis] Abstract

Targeting SMAD3 for Inhibiting Prostate Cancer Metastasis
Scientists found that the MMP9 level, an indicator of the invasiveness of cancer cells, negatively correlates with the activity of phosphorylated SMAD3 levels in the prostate cancer patients. Augmented phosphorylated SMAD3 inhibited MMP9 and invasiveness of PC3 cells, while inhibition of phosphorylated SMAD3 activated MMP9 and promoted PC3 cell invasiveness. [Tumor Biol] Abstract

CLINICAL RESEARCH

Primary Gleason Grade 4 at the Positive Margin Is Associated with Metastasis and Death Among Patients with Gleason 7 Prostate Cancer Undergoing Radical Prostatectomy
Investigators evaluated the association of primary Gleason grade at the site of positive surgical margin (PSM) with subsequent clinical progression and mortality among patients with Gleason score 7 prostate cancer. [Eur Urol] Abstract

Clinical Activity of Enzalutamide versus Docetaxel in Men with Castration-Resistant Prostate Cancer Progressing after Abiraterone
Investigators evaluated the clinical activity of enzalutamide versus docetaxel in men with metastatic castration-resistant prostate cancer who progressed on abiraterone [Prostate] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Lilly and Immunocore Enter Immunotherapy Agreement to Co-Discover and Co-Develop Novel Cancer Therapies
Eli Lilly and Company and Immunocore Limited announced they have entered into a co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapies. Using Immunocore’s Immune Mobilizing Monoclonal T-Cell Receptor Against Cancer technology, the companies will seek to use the power of the body’s own immune system to attack cancer cells. [Eli Lilly and Company] Press Release

A*STAR Partners with Roche to Develop New Cancer Therapeutics
A*STAR’s Bioprocessing Technology Institute has entered into an agreement with Roche to identify novel drug candidates for the detection and treatment of cancer. [Agency for Science, Technology and Research (A*STAR)] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

Product Marketing Manager (Cesca Therapeutics)

Postdoctoral Position – Cancer Biology/Genomics (Cornell University)

Postgraduate Position – Investigation into Chemokine Receptor Induced Cell Migration (University of East Anglia)

Postdoctoral Research Fellow – Mechanism of Gene Regulation in Prostate Cancer Development and Bone Metastasis (Brigham & Women’s Hospital – Harvard Medical School)

PhD Studentship – Cancer Cell Biology (Queensland University of Technology – Translational Research Institute)

Associate Research Scientist – Molecular Mechanisms that Regulate Prostate Tumor Initiation and Formation of Cancer Stem Cells (Columbia University)

Postdoctoral Fellow – Computational Biology (Netherlands Cancer Institute)

Postdoctoral Fellow – Prostate Cancer Research (Institute of Oncology Research)

PhD Student – Detection of Novel Prostate Cancer Biomarkers (University of Bath)

Postdoctoral Fellow – Translational Prostate Cancer (Cleveland Clinic)

Postdoctoral Fellow – Prostate Cancer Research (Henry Ford Hospital)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development: High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.